07:13 AM EDT, 10/28/2024 (MT Newswires) -- AstraZeneca ( AZN ) said on Monday that its drug Fasenra has been approved in the European Union as an additional treatment for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis, a serious immune-related condition.

The company said the decision follows a positive opinion from the Committee for Medicinal Products for Human Use and is based on a phase III trial that showed nearly 60% of patients treated with Fasenra achieved remission and 41% fully stopped taking oral corticosteroids.

Price: 74.93, Change: -0.12, Percent Change: -0.16